Roy Bicknell studied chemistry and for doctorate at St. John’s College Oxford. He received his MA and D. Phil in 1984. His doctoral studies where in mechanisms of b-lactamase resistance. He then won a NATO fellowship to Harvard Medical School where he worked from 1984 to 1989. Initially still interested in enzyme mechanisms he soon turned his attention to angiogenesis and angiogenic factors. He returned to the new Institute of Molecular Medicine in Oxford as a group head with the Imperial Cancer Research Fund. He remained in Oxford for fifteen years where he developed an international reputation in the field of Angiogenesis and was in time appointed Professor of Cancer Cell Biology. His early work involved angiogenic factors such as VEGF and thymidine phosphorylase. More recently he became interested in the identification of novel genes involved in endothelial biology and angiogenesis and particularly those that have potential as cancer targets. His group has identified several such genes including Delta4, Robo4, EndoPDI and ECSCR.
Roy moved to Birmingham in 2005 where he has continued the identification of novel genes and recently developed an interest in modern techniques of genomics including deep sequencing.
Roy is interested in supervising doctoral research students in the following areas:
The characterisation of novel genes and regulators in angiogenesis
Transcriptomic profiling of the tumour vasculature
If you are interesting in studying any of these subject areas please contact Roy on the contact details above, or for any general doctoral research enquiries, please email: email@example.com or call +44 (0)121 414 5005.
For a full list of available Doctoral Research opportunities, please visit our doctoral opportunities web site.
Bioinformatic methods for finding differentially expressed genes in cDNA libraries applied to the identification of tumour vascular targets.
Herbert JM, Stekel DJ, Mura M, Sychev M, Bicknell R
Methods Mol Biol. 2011 729, 99-119
RhoJ/TCL regulates endothelial motility and tube formation and modulates actomyosin contractility and focal adhesion numbers
Kaur S, Leszczynska K, Abraham S, Scarcia M, Hiltbrunner S, Marshall CJ, Mavria G, Bicknell R, Heath VL
Arterioscler Thromb Vasc Biol 2011 31, 657-64
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependant manner.
Mee CJ, Farquar MJ, Harris HJ, Hu K, Ramma W, Ahmed A, Maurel P, Bicknell R, Balfe P, McKeating JA
Gastroenterology, 2010 138, 1134-42
A new procedure for determining the genetic basis of a physiological process in a non-model species illustrated by cold induced angiogenesis in the carp.
Herbert JMJ, Buffa FM, Vorschmitt H, Egginton S, Bicknell R
BMC Genomics, 2009 10, 490
Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.
Maloney SL, Sullivan DC, Suchting S, Herbert JM, Rabai EM, Nagy Z, Barker J, Sundar S, Bicknell R.
Br J Cancer. 2009 Sep 15;101(6):957-66.
Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors.
Sheldon H, Andre M, Legg JA, Heal P, Herbert JM, Sainson R, Sharma AS, Kitajewski JK, Heath VL, Bicknell R.
FASEB J. 2009 Feb;23(2):513-22.
ECSM2, an endothelial specific filamin a binding protein that mediates chemotaxis.
Armstrong LJ, Heath VL, Sanderson S, Kaur S, Beesley JF, Herbert JM, Legg JA, Poulsom R, Bicknell R.
Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1640-6.
A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes.
Herbert JM, Stekel D, Sanderson S, Heath VL, Bicknell R.
BMC Genomics. 2008 Apr 7;9:153.